<code id='1490BD4CB9'></code><style id='1490BD4CB9'></style>
    • <acronym id='1490BD4CB9'></acronym>
      <center id='1490BD4CB9'><center id='1490BD4CB9'><tfoot id='1490BD4CB9'></tfoot></center><abbr id='1490BD4CB9'><dir id='1490BD4CB9'><tfoot id='1490BD4CB9'></tfoot><noframes id='1490BD4CB9'>

    • <optgroup id='1490BD4CB9'><strike id='1490BD4CB9'><sup id='1490BD4CB9'></sup></strike><code id='1490BD4CB9'></code></optgroup>
        1. <b id='1490BD4CB9'><label id='1490BD4CB9'><select id='1490BD4CB9'><dt id='1490BD4CB9'><span id='1490BD4CB9'></span></dt></select></label></b><u id='1490BD4CB9'></u>
          <i id='1490BD4CB9'><strike id='1490BD4CB9'><tt id='1490BD4CB9'><pre id='1490BD4CB9'></pre></tt></strike></i>

          knowledge

          knowledge

          author:leisure time    Page View:311
          In this photo illustration, Farxiga, Xarelto, Entresto, and Eliquis are made available to customers at the New City Halsted Pharmacy on August 29, 2023 in Chicago, Illinois. These are 4 of 10 prescription drugs that will be subject to Medicare price negotiations under the Inflation Reduction Act. The other drugs include Jardiance, Enbrel, Januvia, Imbruvica, Stelara and Fiasp.
          Scott Olson/Getty Images

          WASHINGTON  — The Biden administration is making its opening offers to pharmaceutical companies in its brand-new Medicare drug price negotiation program on Thursday, administration officials said. And that’s about all they said.

          The offers will not be made public unless a manufacturer chooses to publicly disclose information about the talks, a senior administration official said. Companies have until March 2 to either accept the government’s offer or propose a counteroffer. The Biden administration will publish the final prices by Sept. 1 of this year after the negotiation process ends. 

          advertisement

          The negotiated prices won’t take effect until 2026. 

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          Walensky prepares to leave CDC — and Congress — behind
          Walensky prepares to leave CDC — and Congress — behind

          OutgoingCDCDirectorRochelleWalenskyJIMWATSON/AFPviaGettyImagesRochelleWalensky,theoutgoingdirectorof

          read more
          The woman behind the Dana Farber
          The woman behind the Dana Farber

          LaurieGlimcher,CEOofDanaFarberCancerInstitute,isthearchitectofthebiggestshakeupinBostonhealthcareind

          read more
          Psychedelics group wrestles with new pharma identity
          Psychedelics group wrestles with new pharma identity

          OliviaGoldhill/STATDENVER—Hecouldhavebeenarockstar,areligiousicon,thewayecstaticapplausefromthousand

          read more

          Elevance, private equity launch primary care company

          MichaelConroy/APThesedays,thesurefirewaytogetaheadinhealthinsuranceistobecomeahealthcareprovider,and